Latest Oncology News

Five Under 5: Top Oncology Videos for the Week of 3/30

April 6th 2025

Kristi Rosa

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

IO Research Pays Off in MSI-H/dMMR CRC but Misses the Mark in MSS/pMMR Disease

April 6th 2025

Ashling Wahner

Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.

The OncFive: Top Oncology Articles for the Week of 3/30

April 5th 2025

Kristi Rosa

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

Oral Decitabine/Cedazuridine Is an Effective, At-Home Treatment Option for MDS and CMML

April 5th 2025

Courtney Flaherty

James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.

Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology

April 5th 2025

Kristi Rosa

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Latest Oncology Videos

Dr Herzberg on the Distinctions Between Sotorasib and Adagrasib for KRAS G12C+ NSCLC

Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

Dr Pietrantonio on Future Directions of Evaluating Amivantamab in CRC

Future Considerations for Treatment Sequencing in B-ALL

Ongoing Research to Watch in Ovarian Cancer in 2025

Dr Dreyling on the Expanding Role of BTK Inhibitors in the Treatment of MCL

Dr Grisham on the Safety of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer

Dr Albiges on the Efficacy of Lenvatinib Plus Belzutifan in ccRCC

Dr Yu on the Evolving Role of AR Inhibitors and Degraders in Metastatic Prostate Cancer

Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center

Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

Dr McLornan on the Future of an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

Dr Farid on the Efficacy of MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

Dr Davila on the Future Use of Biomarkers to Predict CAR T-Cell Therapy Resistance in LBCL

Dr Shore on the Importance of Addressing Gaps in Prostate Cancer Management

Dr Van Gorp on the Role of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

Highlighting Key Ovarian Cancer Data from the 2025 SGO Annual Meeting

Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer

PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer

MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer

Expert Insights for Approaching Patient Counseling for CAR T-Cell Therapy in R/R DLBCL

Selecting Candidates for CAR T-Cell Therapy in R/R DLBCL: Patient Characteristics, Eligibility, and Timing Considerations

Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN

All Oncology News

FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL

April 4th 2025

Kristi Rosa

A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.

AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs

April 4th 2025

Jax DiEugenio

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

Perioperative Durvalumab-Based Regimen Receives European Approval for Resectable NSCLC

April 4th 2025

Caroline Seymour

Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.

T-DXd Wins EU Approval for HR+, HER2-Low or -Ultralow Metastatic Breast Cancer After Endocrine Therapy

April 4th 2025

Chris Ryan

The European Commission approved trastuzumab deruxtecan for HR-positive, HER2-low or -ultralow metastatic breast cancer after at least 1 endocrine therapy.

Fox Chase Cancer Center Study Shows That Examining More Lymph Nodes Was Associated With Improved Outcomes for Patients With Colon Cancer

April 4th 2025

Fox Chase Cancer Center

Removing and testing more lymph nodes during surgery was associated with more accurate staging and better survival rates for patients with colon cancer.

Chemotherapy-Free Combos Lead the Way in R/R Follicular Lymphoma

April 4th 2025

Kyle Doherty

OncologyLive was onsite at the 2024 ASH Annual Meeting to film a Peer Exchange featuring expert commentary on follicular lymphoma.

Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL

April 4th 2025

Kyle Doherty

Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Caroline Seymour

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD

April 3rd 2025

Chandler Park, MD, MSc, FACP

Dr Park discusses the core regimens in the current frontline bladder cancer treatment paradigm and ways that this paradigm is expected to evolve.

Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer

April 3rd 2025

Kyle Doherty

Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.

Kidney Cancer Awareness Month Spotlights Early Symptom Recognition, Current Challenges, and Key Treatment Advancements

April 3rd 2025

Courtney Flaherty

I. Alex Bowman, MD, underscores how Kidney Cancer Awareness Month enables earlier disease detection, promotes patient education, and drives vital research.

FDA Gives RPDD to NEO100 for Pediatric-Type Diffuse High-Grade Glioma

April 3rd 2025

Ashley Chan

NEO100 was given rare pediatric disease designation by the FDA for the treatment of patients with pediatric-type diffuse high-grade glioma.

Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma

April 3rd 2025

Ashling Wahner

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Brain Imaging Plus Virtual Reality Shows Promise for Effectively Managing Cancer Pain

April 3rd 2025

Roswell Park Comprehensive Cancer Center

Roswell Park-led study takes a significant step toward relief without opioid.

Avutometinib/Defactinib Combo Shows Potential in Recurrent Mesonephric Gynecologic Cancer

April 3rd 2025

Jax DiEugenio

Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.

See All News